Soleno Therapeutics (SLNO) Other financing activities (2014 - 2026)

Soleno Therapeutics (SLNO) has 10 years of Other financing activities data on file, last reported at $52000.0 in Q1 2026.

• On a quarterly basis, Other financing activities fell 80.67% year-over-year to $52000.0 in Q1 2026; TTM through Mar 2026 was $17.0 million, a 981.85% increase from a year earlier, with the FY2025 full-year figure at $17.2 million, up 1207.14% from the prior year.
• Other financing activities for Q1 2026 stood at $52000.0, down from $954000.0 in the prior quarter.
• Over the last five years, Other financing activities for SLNO reached as high as $13.7 million in Q2 2025 and fell as low as -$1000.0 in Q4 2024.
• Historically, Other financing activities has averaged $2.3 million across 5 years, with a median of $437000.0 in 2023.
• Across the five-year window, Other financing activities sank 100.3% in 2024 and soared 95500.0% in 2025, its largest moves.
• Year by year, Other financing activities stood at $16000.0 in 2022, then surged by 2006.25% to $337000.0 in 2023, then slumped by 100.3% to -$1000.0 in 2024, then surged by 95500.0% to $954000.0 in 2025, then sank by 94.55% to $52000.0 in 2026.
• Per Business Quant data, the three most recent Other financing activities figures were $52000.0 in Q1 2026, $954000.0 in Q4 2025, and $2.3 million in Q3 2025.